Strides Pharma Science’s step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received tentative United States Food & Drug Administration (FDA) approval for triamcinolone acetonide ointment USP, 0.05%.
Triamcinolone acetonide ointment is in a class of medications called corticosteroids.
It is used to treat itching, redness, dryness, crusting, scaling, inflammation and is comfort of various skin conditions, including psoriasis.
“While it was amongst the few competitive generic therapy designated products for Strides, another generic company received approval prior to our approval,” the company said in a BSE filing.
Consequently, the final approval for Strides Pharma will be effective 30 May 2020, when the company will launch the product.
The product will be manufactured at the company’s oral dosage facility at Bengaluru and will be marketed by Strides Pharma Inc in the US market.
According to IQVIA MAT data, the US market for triamcinolone acetonide ointment USP, 0.05% is approximately US$ 20 million.